Test Code ACRNS Acylcarnitines, Quantitative, Serum
Necessary Information
1. Patient's age is required.
2. Include family history, clinical condition (asymptomatic or acute episode), diet, and drug therapy information.
Specimen Required
Patient Preparation: Collect specimen just prior to a scheduled meal or feeding.
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.1 mL
Collection Instructions: Centrifuge and aliquot serum into plastic vial.
Useful For
Diagnosis of fatty acid oxidation disorders and several organic acidurias using serum specimens
Evaluating treatment during follow-up of patients with fatty acid beta-oxidation disorders and several organic acidurias
Method Name
Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
Reporting Name
Acylcarnitines, Quantitative, SSpecimen Type
SerumSpecimen Minimum Volume
0.04 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Frozen (preferred) | 60 days | |
Refrigerated | 21 days | ||
Ambient | 72 hours |
Reference Values
≤7 days (nmol/mL) |
8 days-7 years (nmol/mL) |
≥8 years (nmol/mL) |
|
Acetylcarnitine, C2 |
2.14-15.89 |
2.00-27.57 |
2.00-17.83 |
Acrylylcarnitine, C3:1 |
<0.04 |
<0.05 |
<0.07 |
Propionylcarnitine, C3 |
<0.55 |
<1.78 |
<0.88 |
Formiminoglutamate, FIGLU |
<0.43 |
<0.08 |
<0.14 |
Iso-/Butyrylcarnitine, C4 |
<0.46 |
<1.06 |
<0.83 |
Tiglylcarnitine, C5:1 |
<0.05 |
<0.09 |
<0.11 |
Isovaleryl-/2-Methylbutyrylcarn C5 |
<0.38 |
<0.63 |
<0.51 |
3-OH-iso-/butyrylcarnitine, C4-OH |
<0.13 |
<0.51 |
<0.18 |
Hexenoylcarnitine, C6:1 |
<0.12 |
<0.10 |
<0.15 |
Hexanoylcarnitine, C6 |
<0.14 |
<0.23 |
<0.17 |
3-OH-isovalerylcarnitine, C5-OH |
<0.08 |
<0.12 |
<0.10 |
Benzoylcarnitine |
<0.13 |
<0.07 |
<0.10 |
Heptanoylcarnitine, C7 |
<0.05 |
<0.05 |
<0.06 |
3-OH-hexanoylcarnitine, C6-OH |
<0.08 |
<0.19 |
<0.09 |
Phenylacetylcarnitine |
<0.15 |
<0.22 |
<0.29 |
Salicylcarnitine |
<0.08 |
<0.09 |
<0.09 |
Octenoylcarnitine, C8:1 |
<0.48 |
<0.91 |
<0.88 |
Octanoylcarnitine, C8 |
<0.19 |
<0.45 |
<0.78 |
Malonylcarnitine, C3-DC |
<0.09 |
<0.14 |
<0.26 |
Decadienoylcarnitine, C10:2 |
<0.11 |
<0.12 |
<0.26 |
Decenoylcarnitine, C10:1 |
<0.25 |
<0.46 |
<0.47 |
Decanoylcarnitine, C10 |
<0.27 |
<0.91 |
<0.88 |
Methylmalonyl-/succinylcarn, C4-DC |
<0.05 |
<0.05 |
<0.05 |
3-OH-decenoylcarnitine, C10:1-OH |
<0.12 |
<0.12 |
<0.13 |
Glutarylcarnitine, C5-DC |
<0.06 |
<0.10 |
<0.11 |
Dodecenoylcarnitine, C12:1 |
<0.19 |
<0.37 |
<0.35 |
Dodecanoylcarnitine, C12 |
<0.18 |
<0.35 |
<0.26 |
3-Methylglutarylcarnitine, C6-DC |
<0.28 |
<0.21 |
<0.43 |
3-OH-dodecenoylcarnitine, C12:1-OH |
<0.11 |
<0.10 |
<0.13 |
3-OH-dodecanoylcarnitine, C12-OH |
<0.06 |
<0.09 |
<0.08 |
Tetradecadienoylcarnitine, C14:2 |
<0.09 |
<0.13 |
<0.18 |
Tetradecenoylcarnitine, C14:1 |
<0.16 |
<0.35 |
<0.24 |
Tetradecanoylcarnitine, C14 |
<0.11 |
<0.15 |
<0.12 |
Octanedioylcarnitine, C8-DC |
<0.25 |
<0.19 |
<0.19 |
3-OH-tetradecenoylcarnitine C14:1OH |
<0.06 |
<0.18 |
<0.13 |
3-OH-tetradecanoylcarnitine, C14-OH |
<0.04 |
<0.05 |
<0.08 |
Hexadecenoylcarnitine, C16:1 |
<0.15 |
<0.21 |
<0.10 |
Hexadecanoylcarnitine, C16 |
<0.36 |
<0.52 |
<0.23 |
3-OH-hexadecenoylcarnitine,C16:1-OH |
<0.78 |
<0.36 |
<0.06 |
3-OH-hexadecanoylcarnitine, C16-OH |
<0.10 |
<0.07 |
<0.06 |
Octadecadienoylcarnitine, C18:2 |
<0.12 |
<0.31 |
<0.24 |
Octadecenoylcarnitine, C18:1 |
<0.25 |
<0.45 |
<0.39 |
Octadecanoylcarnitine, C18 |
<0.10 |
<0.12 |
<0.14 |
Dodecanedioylcarnitine, C12-DC |
<0.10 |
<0.04 |
<0.04 |
3-OH-octadecadienoylcarn, C18:2-OH |
<0.04 |
<0.06 |
<0.06 |
3-OH-octadecenoylcarnitine C18:1-OH |
<0.03 |
<0.04 |
<0.06 |
3-OH-octadecanoylcarnitine, C18-OH |
<0.03 |
<0.05 |
<0.03 |
Interpretation
An interpretive report will be provided. The individual quantitative results support the interpretation of the acylcarnitine profile but are not diagnostic by themselves. The interpretation is based on pattern recognition.
Abnormal results are not sufficient to conclusively establish a diagnosis of a particular disease. To verify a preliminary diagnosis based on an acylcarnitine analysis, independent biochemical (eg, in vitro enzyme assay) or molecular genetic analyses are required.
Clinical Reference
1. Miller MJ, Cusmano-Ozog K, Oglesbee D, Young S; ACMG Laboratory Quality Assurance Committee. Laboratory analysis of acylcarnitines, 2020 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(2):249-258
2. Matern D. Acylcarnitines, including in vitro loading tests. In: Blau N, Duran M, Gibson KM, eds. Laboratory Guide to the Methods in Biochemical Genetics. Springer Verlag; 2008:171-206
3. Rinaldo P, Cowan TM, Matern D. Acylcarnitine profile analysis. Genet Med. 2008;10(2):151-156
4. Smith EH, Matern D. Acylcarnitine analysis by tandem mass spectrometry. Curr Protoc Hum Genet. 2010;Chap 17:Unit 17.8.1-20
5. Elizondo G, Matern D, Vockley J, Harding CO, Gillingham MB. Effects of fasting, feeding and exercise on plasma acylcarnitines among subjects with CPT2D, VLCADD and LCHADD/TFPD. Mol Genet Metab. 2020;131(1-2):90-97
Day(s) Performed
Monday through Friday
Report Available
2 to 5 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
82017
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
ACRNS | Acylcarnitines, Quantitative, S | 43433-2 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
92134 | Acetylcarnitine, C2 | 30191-1 |
92135 | Acrylylcarnitine, C3:1 | 43235-1 |
92136 | Propionylcarnitine, C3 | 30551-6 |
92137 | Formiminoglutamate, FIGLU | 79628-4 |
92138 | Iso-/Butyrylcarnitine, C4 | 35655-0 |
92139 | Tiglylcarnitine, C5:1 | 51416-6 |
92140 | Isovaleryl-/2-Methylbutyrylcarn C5 | 30531-8 |
92141 | 3-OH-iso-/butyrylcarnitine, C4-OH | 39000-5 |
92142 | Hexenoylcarnitine, C6:1 | 74540-6 |
92143 | Hexanoylcarnitine, C6 | 30358-6 |
92144 | 3-OH-isovalerylcarnitine, C5-OH | 39001-3 |
92145 | Benzoylcarnitine | 39615-0 |
92146 | Heptanoylcarnitine, C7 | 55871-8 |
92147 | 3-OH-hexanoylcarnitine, C6-OH | 30236-4 |
92148 | Phenylacetylcarnitine | 90237-9 |
92149 | Salicylcarnitine | 90238-7 |
92150 | Octenoylcarnitine, C8:1 | 30541-7 |
92151 | Octanoylcarnitine, C8 | 30540-9 |
92152 | Malonylcarnitine, C3-DC | 55940-1 |
92153 | Decadienoylcarnitine, C10:2 | 53471-9 |
92154 | Decenoylcarnitine, C10:1 | 30328-9 |
92155 | Decanoylcarnitine, C10 | 30327-1 |
92156 | Methylmalonyl-/succinylcarn, C4-DC | 51415-8 |
92157 | 3-OH-decenoylcarnitine, C10:1-OH | 82478-9 |
92158 | Glutarylcarnitine, C5-DC | 30349-5 |
92159 | Dodecenoylcarnitine, C12:1 | 30332-1 |
92160 | Dodecanoylcarnitine, C12 | 30331-3 |
92161 | 3-Methylglutarylcarnitine, C6-DC | 39002-1 |
92162 | 3-OH-dodecenoylcarnitine, C12:1-OH | 59195-8 |
92163 | 3-OH-dodecanoylcarnitine, C12-OH | 30233-1 |
92164 | Tetradecadienoylcarnitine, C14:2 | 30564-9 |
92165 | Tetradecenoylcarnitine, C14:1 | 30566-4 |
92166 | Tetradecanoylcarnitine, C14 | 30565-6 |
92167 | Octanedioylcarnitine, C8-DC | 39014-6 |
92168 | 3-OH-tetradecenoylcarnitine C14:1OH | 30190-3 |
92169 | 3-OH-tetradecanoylcarnitine, C14-OH | 30238-0 |
92170 | Hexadecenoylcarnitine, C16:1 | 30357-8 |
92171 | Hexadecanoylcarnitine, C16 | 30356-0 |
92172 | 3-OH-hexadecenoylcarnitine,C16:1-OH | 30235-6 |
92173 | 3-OH-hexadecanoylcarnitine, C16-OH | 30234-9 |
92174 | Octadecadienoylcarnitine, C18:2 | 30534-2 |
92175 | Octadecenoylcarnitine, C18:1 | 30542-5 |
92176 | Octadecanoylcarnitine, C18 | 30560-7 |
92177 | Dodecanedioylcarnitine, C12-DC | 55855-1 |
92178 | 3-OH-octadecadienoylcarn, C18:2-OH | 30237-2 |
92179 | 3-OH-octadecenoylcarnitine C18:1-OH | 30312-3 |
92180 | 3-OH-octadecanoylcarnitine, C18-OH | 35656-8 |
92181 | Comment (ACRNS) | 46252-3 |
Forms
If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request (T798) with the specimen.